Search results
Search for "aldol condensation" in Full Text gives 83 result(s) in Beilstein Journal of Organic Chemistry.
Syntheses and applications of furanyl-functionalised 2,2’:6’,2’’-terpyridines
- Jérôme Husson and
- Michael Knorr
Beilstein J. Org. Chem. 2012, 8, 379–389, doi:10.3762/bjoc.8.41
- [14]. This strategy was also successfully applied to the preparation of some furanyl-substituted terpyridines. The synthetic sequence starts from furanyl aldehydes 1–3 and 2-acetylpyridine (4). The first step is a base-mediated aldol-condensation that yields the α,β unsaturated ketones 5–7. Reacting
Graphical Abstract
Figure 1: Structure and atomic numbering of 2,2’:6’,2’’-terpyridines.
Scheme 1: Synthesis of furanyl-substituted terpyridines 12–14 by using Kröhnke’s method.
Scheme 2: Synthesis of terpyridines under solvent-free conditions.
Scheme 3: Preparation of 4,4′,4′′-trisubstituted terpyridine containing carboxylate moieties.
Scheme 4: Synthetic pathway for the preparation of a furanyl-functionalised quinquepyridine.
Scheme 5: Utilization of an iminium salt in the preparation of a furanyl-substituted tpy.
Figure 2: Chemical structure of U- and S-shaped isomers.
Scheme 6: Preparation of an asymmetric furanyl-substituted terpyridine.
Scheme 7: Synthesis of tpy by Stille cross-coupling reaction.
Scheme 8: Oxidation of the furan ring of furanyl-substituted terpyridines.
Scheme 9: Direct oxidation of a furan ring attached on Ru(II) tpy complexes.
Figure 3: Example of polyoxometalate frameworks functionalised with tpy ligands and tpy-complex (reprinted wi...
Scheme 10: Synthetic pathway to europium(III) and samarium(III) chelates 56 and 57.
Scheme 11: Synthetic pathway to prepare thiocyanato-functionalised tpys as potential biomolecule-labelling age...
Scheme 12: Synthetic sequence envisioned for biomolecules labelling by click-chemistry.
Figure 4: Structure of pyrrolyl (66), thienyl (67) and bithienyl (68)-substituted complexes analogous to comp...
Aldol elaboration of 4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridin-4-ones, masked precursors to acylpyridones
- Raymond C. F. Jones,
- Abdul K. Choudhury,
- James N. Iley,
- Mark E. Light,
- Georgia Loizou and
- Terence A. Pillainayagam
Beilstein J. Org. Chem. 2012, 8, 308–312, doi:10.3762/bjoc.8.33
- MK7 6AA, United Kingdom EPSRC National Crystallography Service, School of Chemistry, University of Southampton, Highfield, Southampton, SO17 1BJ, United Kingdom 10.3762/bjoc.8.33 Abstract A core 4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridine-4-one scaffold is elaborated at C-3(Me) by base-mediated aldol
- condensation to give new 3-alkenyl-4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridine-4-ones, which are masked forms related to the acylpyridone natural products. Keywords: aldol reaction; fused-ring systems; heterocycles; isoxazole; metalation; pyridone; Introduction The 3-acyl-4-hydroxypyridin-2-one moiety 1
Graphical Abstract
Figure 1: The 3-acyl-4-hydroxypyridin-2-one motif, example natural products and the isoxazolopyridone scaffol...
Scheme 1: Aldol reactions of tetrahydroisoxazolopyridone 6. Reagents: (i) LDA–TMEDA, RCHO, THF, −20 °C; (ii) ...
Figure 2: X-ray crystal structure of 3-(2-phenylethenyl)-4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridin-4-one (8a) ...
Figure 3: Ilicicolin H as an example of a 3-decalinoyl-4-hydroxypyridin-2-one metabolite.
Scheme 2: Retrosynthetic analysis of a model 3-decalinyl-4,5,6,7-tetrahydroisoxazolopyridone 10.
Scheme 3: Synthesis of triene 11. Reagents: (i), LDA, propenal, THF, −78 °C; (ii), LiAlH4, THF, 20 °C (75%); ...
Coupled chemo(enzymatic) reactions in continuous flow
- Ruslan Yuryev,
- Simon Strompen and
- Andreas Liese
Beilstein J. Org. Chem. 2011, 7, 1449–1467, doi:10.3762/bjoc.7.169
- formate decarboxylase (BFD) catalyzing the (S)-selective aldol condensation of benzaldehyde (33) and acetaldehyde (32) with formation of (S)-2-hydroxy-1-phenyl-propanone (34) (Scheme 11). In the second vessel the intermediate (S)-34 was asymmetrically reduced by recLb-alcohol dehydrogenase (ADH) and the
Graphical Abstract
Figure 1: Metabolic pathways in a living cell as an example of efficient coupled-reaction processes. A: Subst...
Figure 2: Four generations of biotransformations. I: Single-reaction processes; II: Single-reaction processes...
Scheme 1: Production of L-leucine (3) in a continuously operating enzyme membrane reactor (EMR). E1: L-Leucin...
Scheme 2: Production of D-mandelic acid (5) in a continuously operating enzyme membrane reactor. E1: D-(−)-Ma...
Scheme 3: Simultaneous synthesis of gluconic acid (9) and glutamic acid (8) in a continuously operated membra...
Scheme 4: Production of L-tert-leucine (11) in a continuously operated enzyme membrane reactor equipped with ...
Scheme 5: Continuous oxidation of lactose (12) to lactobionic acid (13) in a dynamic membrane-aerated reactor...
Scheme 6: Production of N-acetylneuraminic acid (17) in a continuously operated enzyme membrane reactor. E1: ...
Scheme 7: Chemo-enzymatic epoxidation of 1-methylcyclohexene (18) in a packed-bed reactor (PBR) containing No...
Scheme 8: Continuous production of (R)-1-phenylethyl propionate (24) by dynamic kinetic resolution of (rac)-1...
Scheme 9: Synthesis of D-xylulose (28) from D,L-serine (26) and D,L-glyceraldehyde (25) in a continuously ope...
Scheme 10: Continuous production of L-alanine (31) from fumarate (29) in a two-stage enzyme membrane reactor. ...
Scheme 11: Continuous synthesis of 1-phenyl-(1S,2S)-propanediol (35) in a cascade of two enzyme membrane react...
Scheme 12: Production of a dipeptide 39 in a cascade of two continuously operated membrane reactors. E1: Carbo...
Scheme 13: Continuous production of GDP-mannose (43) from mannose 1-phosphate (40) in a cascade of two enzyme ...
Scheme 14: Continuous solvent-free chemo-enzymatic synthesis of ethyl (S)-3-(benzylamino)butanoate (48) in a s...
Scheme 15: Continuous chemo-enzymatic synthesis of grossamide (52) in a cascade of packed-bed reactors. E: Per...
Scheme 16: Chemo-enzymatic synthesis of 2-aminophenoxazin-3-one (56) in a cascade of continuously operating pa...
Scheme 17: Continuous conversion of 3-phospho-D-glycerate (57) into D-ribulose 1,5-bisphosphate (58) in a casc...
Scheme 18: Continuous hydrolysis of 4-cyanopyridine (59) to isonicotinic acid (61) in a cascade of two packed-...
Scheme 19: Continuous fermentative production of ethanol (64) from hardwood lignocellulose (62) in a stirred-t...
Scheme 20: Production of hydrogen by anaerobic fermentation of glucose (7) using Clostridium acetobutylicum ce...
Scheme 21: Continuous production of (2R,5R)-hexanediol (67) in an enzyme membrane reactor containing whole cel...
Scheme 22: Synthesis of L-phenylalanine (69) in a continuously stirred tank reactor equipped with a hollow-fib...
Scheme 23: Continuous epoxidation of 1,7-octadiene (70) to (R)-7-epoxyoctene (72) by a strain of Pseudomonas o...
Scheme 24: Oxidation of styrene (73) to (S)-styrene oxide (74) in a continuously operated biofilm tube reactor...
Scheme 25: Reduction of estrone (75) to β-estradiol (76) by Saccharomyces cerevisiae in a cascade of two stirr...
A racemic formal total synthesis of clavukerin A using gold(I)-catalyzed cycloisomerization of 3-methoxy-1,6-enynes as the key strategy
- Jae Youp Cheong and
- Young Ho Rhee
Beilstein J. Org. Chem. 2011, 7, 740–743, doi:10.3762/bjoc.7.84
- in the formal synthesis of clavukerin A was explored. We first investigated the cyclization–hydrogenation strategy (path A in Scheme 4). Deprotection of 4 and the aldol condensation of the resulting diketone under basic conditions proceeded smoothly to give the enone 2 in good yield. However
Graphical Abstract
Scheme 1: Retrosynthetic analysis.
Scheme 2: Preparation of compound 5.
Scheme 3: Synthesis of the cycloheptenone 4.
Scheme 4: Completion of the formal synthesis of clavukerin A.
Construction of cyclic enones via gold-catalyzed oxygen transfer reactions
- Leping Liu,
- Bo Xu and
- Gerald B. Hammond
Beilstein J. Org. Chem. 2011, 7, 606–614, doi:10.3762/bjoc.7.71
- and the final product 4. The isolated intermediate 5 could be transformed into a mixture of 6 and 4 under the reaction conditions, finally yielding 4 via intramolecular aldol condensation. This gold-catalyzed cyclization of alkynyl ketones to enones was successfully utilized in a cascade reaction by
- before being transformed into the final product via intramolecular aldol condensation. Fiksdahl and co-workers investigated a similar gold-catalyzed transformation of internal 1,6-diynes 18 in methanol at room temperature (Scheme 14) [50][51]. Interestingly, a non-conjugated five-membered cyclic enone 19
Graphical Abstract
Scheme 1: Lewis acid or Brønsted acid-catalyzed alkyne–carbonyl metathesis and a proposed [2 + 2] intermediat...
Scheme 2: Gold-catalyzed cyclization of internal alkynyl ketones.
Scheme 3: Proposed [2 + 2] mechanism for the cyclization of alkynyl ketones.
Scheme 4: Gold-catalyzed cyclization of terminal alkynyl ketones.
Scheme 5: Gold-catalyzed tandem oxygen transfer/Nazarov cyclizations.
Scheme 6: TfOH-mediated cyclization of alkynyl ketones.
Scheme 7: Gold-catalyzed cyclizations of 2-alkynyl-1,5-diketones.
Scheme 8: Designed isotopic labeling experiment for mechanistic studies.
Scheme 9: 18O isotopic experiments.
Scheme 10: B2PLYP/6-311+G(d,p)//B2PLYP/6-31G(d) computed reaction profile, relative energies in kcal/mol.
Scheme 11: Gold-catalyzed cyclization of tethered alkynyl arylaldehydes.
Scheme 12: Gold-catalyzed cyclization of terminal diynes.
Scheme 13: Proposed hydrolysis/cyclization mechanism.
Scheme 14: Gold-catalyzed cyclization of internal diynes.
Scheme 15: Proposed solvolysis/cyclization mechanism.
Scheme 16: Gold-catalyzed cyclization of alkynyl epoxides and the 18O isotopic labeling experiment.
Scheme 17: Proposed oxygen transfer mechanism.
Scheme 18: Gold or silver-catalyzed cyclization of alkynyl epoxides and the corresponding deuterium labeling e...
An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals
- Marcus Baumann,
- Ian R. Baxendale,
- Steven V. Ley and
- Nikzad Nikbin
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
- ] (Figure 3). Structurally, this medication consists of a complex pyrrole-substituted 2-indolinone core which can be prepared by a late stage aldol condensation between a 2-indolinone fragment 42 with the corresponding pyrrole aldehyde 41 (Scheme 7). The oxime functionality in compound 38, which is obtained
- ethyl 2,4-dimethylpyrrole-3-carboxylate which can be formylated at the free ring position by trimethyl orthoformate to yield the fully elaborated pyrrole aldehyde (41). The aforementioned aldol condensation unites both key fragments: Ester hydrolysis and amide formation complete the synthesis (Scheme 7
- oxime 38 under reductive conditions. Deprotection and decarboxylation of the remaining tert-butyl ester produces the desired pyrrole intermediate, which upon treatment with Vilsmeier reagent undergoes a formal acylation. This product is not isolated but reacted directly with 41 in an aldol condensation
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
Asymmetric reactions in continuous flow
- Xiao Yin Mak,
- Paola Laurino and
- Peter H. Seeberger
Beilstein J. Org. Chem. 2009, 5, No. 19, doi:10.3762/bjoc.5.19
- significantly higher when compared to a carousel-type reactor typically used for parallel synthesis. Organocatalytic asymmetric aldol reactions in microflow devices were recently reported by our laboratory [15]. The aldol condensation of various aromatic aldehydes with acetone was carried out at higher
Graphical Abstract
Scheme 1: Enantioselective addition of trimethylsilyl cyanide to benzaldehyde.
Scheme 2: Asymmetric catalytic hydrogenation in a falling-film microreactor.
Scheme 3: Aldol reaction catalyzed by 5-(pyrrolidine-2-yl)tetrazole.
Scheme 4: Enantioselective addition of diethylzinc to aryl aldehydes.
Scheme 5: Glyoxylate-ene reaction in flow.
Scheme 6: Asymmetric synthesis of ß-lactams.
Scheme 7: α-Chlorination of acid chlorides in flow.
Scheme 8: Asymmetric Michael reaction in continuous flow.
Scheme 9: Enantioselective addition of Et2Zn to benzaldehyde using monolithic chiral amino alcohol.
Scheme 10: Continuous-flow hydrolytic dynamic kinetic resolution of epibromohydrin (32).
Scheme 11: Continuous-flow asymmetric cyclopropanation.
Scheme 12: Continuous asymmetric hydrogenation of dimethyl itaconate in scCO2.
Scheme 13: Continuous asymmetric transfer hydrogenation of acetophenone.
Scheme 14: Asymmetric epoxidation using a continuous flow membrane reactor.
Scheme 15: Enzymatic cyanohydrin formation in a microreactor.
Scheme 16: Resolution of (R/S)- 54 with immobilized lipase in a continuous scCO2- flow reactor.
Scheme 17: Enantioselective separation of Acetyl-D-Phe in a continuous flow reactor.
Recent progress on the total synthesis of acetogenins from Annonaceae
- Nianguang Li,
- Zhihao Shi,
- Yuping Tang,
- Jianwei Chen and
- Xiang Li
Beilstein J. Org. Chem. 2008, 4, No. 48, doi:10.3762/bjoc.4.48
Graphical Abstract
Scheme 1: Total synthesis of longifolicin by Marshall’s group.
Scheme 2: Total synthesis of corossoline by Tanaka’s group.
Scheme 3: Total synthesis of corossoline by Wu’s group.
Scheme 4: Total synthesis of pseudo-annonacin A by Hanessian’s group.
Scheme 5: Total synthesis of tonkinecin by Wu’s group.
Scheme 6: Total synthesis of gigantetrocin A by Shi’s group.
Scheme 7: Total synthesis of annonacin by Wu’s group.
Scheme 8: Total synthesis of solamin by Kitahara’s group.
Scheme 9: Total synthesis of solamin by Mioskowski’s group.
Scheme 10: Total synthesis of cis-solamin by Makabe’s group.
Scheme 11: Total synthesis of cis-solamin by Brown’s group.
Scheme 12: The formal synthesis of (+)-cis-solamin by Donohoe’s group.
Scheme 13: Total synthesis of cis-solamin by Stark’s group.
Scheme 14: Total synthesis of mosin B by Tanaka’s group.
Scheme 15: Total synthesis of longicin by Hanessian’s group.
Scheme 16: Total synthesis of murisolin and 16,19-cis-murisolin by Tanaka’s group.
Scheme 17: Synthesis of a stereoisomer library of (+)-murisolin by Curran’s group.
Scheme 18: Total synthesis of murisolin by Makabe’s group.
Scheme 19: Total synthesis of reticulatain-1 by Makabe’s group.
Scheme 20: Total synthesis of muricatetrocin C by Ley’s group.
Scheme 21: Total synthesis of (4R,12S,15S,16S,19R,20R,34S)-muricatetrocin (146) and (4R,12R,15S,16S,19R,20R,34S...
Scheme 22: Total synthesis of parviflorin by Hoye’s group.
Scheme 23: Total synthesis of parviflorin by Trost’s group.
Scheme 24: Total synthesis of trilobacin by Sinha’s group.
Scheme 25: Total synthesis of 15-epi-annonin I 181b by Scharf’s group.
Scheme 26: Total synthesis of squamocin A and squamocin D by Scharf’s group.
Scheme 27: Total synthesis of asiminocin by Marshall’s group.
Scheme 28: Total synthesis of asiminecin by Marshall’s group.
Scheme 29: Total synthesis of (+)-(30S)-bullanin by Marshall’s group.
Scheme 30: Total synthesis of uvaricin by the group of Sinha and Keinan.
Scheme 31: Formal synthesis of uvaricin by Burke’s group.
Scheme 32: Total synthesis of trilobin by Marshall’s group.
Scheme 33: Total synthesis of trilobin by the group of Sinha and Keinan.
Scheme 34: Total synthesis of asimilobin by the group of Wang and Shi.
Scheme 35: Total synthesis of squamotacin by the group of Sinha and Keinan.
Scheme 36: Total synthesis of asimicin by Marshall’s group.
Scheme 37: Total synthesis of asimicin by the group of Sinha and Keinan.
Scheme 38: Total synthesis of asimicin by Roush’s group.
Scheme 39: Total synthesis of asimicin by Marshall’s group.
Scheme 40: Total synthesis of 10-hydroxyasimicin by Ley’s group.
Scheme 41: Total synthesis of asimin by Marshall’s group.
Scheme 42: Total synthesis of bullatacin by the group of Sinha and Keinan.
Scheme 43: Total synthesis of bullatacin by Roush’s group.
Scheme 44: Total synthesis of bullatacin by Pagenkopf’s group.
Scheme 45: Total synthesis of rollidecins C and D by the group of Sinha and Keinan.
Scheme 46: Total synthesis of 30(S)-hydroxybullatacin by Marshall’s group.
Scheme 47: Total synthesis of uvarigrandin A and 5(R)-uvarigrandin A by Marshall’s group.
Scheme 48: Total synthesis of membranacin by Brown’s group.
Scheme 49: Total synthesis of membranacin by Lee’s group.
Scheme 50: Total synthesis of rolliniastatin 1 and rollimembrin by Lee’s group.
Scheme 51: Total synthesis of longimicin D by the group of Maezaki and Tanaka.
Scheme 52: Total synthesis of the structure proposed for mucoxin by Borhan’s group.
Scheme 53: Modular synthesis of adjacent bis-THF annonaceous acetogenins by Marshall’s group.
Scheme 54: Total synthesis of 4-deoxygigantecin by Tanaka’s group.
Scheme 55: Total synthesis of squamostatins D by Marshall’s group.
Scheme 56: Total synthesis of gigantecin by Crimmins’s group.
Scheme 57: Total synthesis of gigantecin by Hoye’s group.
Scheme 58: Total synthesis of cis-sylvaticin by Donohoe’s group.
Scheme 59: Total synthesis of 17(S),18(S)-goniocin by Sinha’s group.
Scheme 60: Total synthesis of goniocin and cyclogoniodenin T by the group of Sinha and Keinan.
Scheme 61: Total synthesis of jimenezin by Takahashi’s group.
Scheme 62: Total synthesis of jimenezin by Lee’s group.
Scheme 63: Total synthesis of jimenezin by Hoffmann’s group.
Scheme 64: Total synthesis of muconin by Jacobsen’s group.
Scheme 65: Total synthesis of (+)-muconin by Kitahara’s group.
Scheme 66: Total synthesis of muconin by Takahashi’s group.
Scheme 67: Total synthesis of muconin by the group of Yoshimitsu and Nagaoka.
Scheme 68: Total synthesis of mucocin by the group of Sinha and Keinan.
Scheme 69: Total synthesis of mucocin by Takahashi’s group.
Scheme 70: Total synthesis of (−)-mucocin by Koert’s group.
Scheme 71: Total synthesis of mucocin by the group of Takahashi and Nakata.
Scheme 72: Total synthesis of mucocin by Evans’s group.
Scheme 73: Total synthesis of mucocin by Mootoo’s group.
Scheme 74: Total synthesis of (−)-mucocin by Crimmins’s group.
Scheme 75: Total synthesis of pyranicin by the group of Takahashi and Nakata.
Scheme 76: Total synthesis of pyranicin by Rein’s group.
Scheme 77: Total synthesis of proposed pyragonicin by the group of Takahashi and Nakata.
Scheme 78: Total synthesis of pyragonicin by Rein’s group.
Scheme 79: Total synthesis of pyragonicin by Takahashi’s group.
Scheme 80: Total synthesis of squamostanal A by Figadère’s group.
Scheme 81: Total synthesis of diepomuricanin by Tanaka’s group.
Scheme 82: Total synthesis of (−)-muricatacin [(R,R)-373a] and its enantiomer (+)-muricatacin [(S,S)-373b] by ...
Scheme 83: Total synthesis of epi-muricatacin (+)-(S,R)-373c and (−)-(R,S)-373d by Scharf’s group.
Scheme 84: Total synthesis of (−)-muricatacin 373a and 5-epi-(−)-muricatacin 373d by Uang’s group.
Scheme 85: Total synthesis of four stereoisomers of muricatacin by Yoon’s group.
Scheme 86: Total synthesis of (+)-muricatacin by Figadère’s group.
Scheme 87: Total synthesis of (+)-epi-muricatacin and (−)-muricatacin by Couladouros’s group.
Scheme 88: Total synthesis of muricatacin by Trost’s group.
Scheme 89: Total synthesis of (−)-(4R,5R)-muricatacin by Heck and Mioskowski’s group.
Scheme 90: Total synthesis of muricatacin (−)-373a by the group of Carda and Marco.
Scheme 91: Total synthesis of (−)- and (+)-muricatacin by Popsavin’s group.
Scheme 92: Total synthesis of (−)-muricatacin by the group of Bernard and Piras.
Scheme 93: Total synthesis of (−)-muricatacin by the group of Yoshimitsu and Nagaoka.
Scheme 94: Total synthesis of (−)-muricatacin by Quinn’s group.
Scheme 95: Total synthesis of montecristin by Brückner’s group.
Scheme 96: Total synthesis of (−)-acaterin by the group of Franck and Figadère.
Scheme 97: Total synthesis of (−)-acaterin by Singh’s group.
Scheme 98: Total synthesis of (−)-acaterin by Kumar’s group.
Scheme 99: Total synthesis of rollicosin by Quinn’s group.
Scheme 100: Total synthesis of Rollicosin by Makabe’s group.
Scheme 101: Total synthesis of squamostolide by Makabe’s group.
Scheme 102: Total synthesis of tonkinelin by Makabe’s group.
